Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ages 19 to 45 inclusive~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations~* Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/ \[height (m)\]2~Exclusion Criteria:~* Women of child-bearing potential (WOCBP) who are unwilling or unable to use acceptable barrier methods (condoms and spermicides) to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product~* Any significant acute or chronic medical illness~* Current or recent (within 3 months) gastrointestinal disease~* Any major surgery within 4 weeks of study drug administration~* History of allergy to Dipeptidyl peptidase 4 (DPP4) inhibitor or related compounds~* History of allergy or intolerance to metformin or other similar acting agents~* Prior exposure to saxagliptin~* Prior exposure to metformin within 3 months of study drug administration~* Estimated creatinine clearance (Clcr) of \< 80ml/min using the Cockcroft Gault formula

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arm A (Type: OTHER): Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions
- Arm B (Type: OTHER): Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions
- Arm C (Type: OTHER): Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal
- Arm D (Type: OTHER): Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal

Based on this trial design, predict the completion outcome and termination type (if applicable).